A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
Public ClinicalTrials.gov record NCT06257264. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1a/1b Study of BG-68501, a Selective CDK2 Inhibitor, in Participants With Advanced Solid Tumors
Study identification
- NCT ID
- NCT06257264
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- BeiGene
- Industry
- Enrollment
- 258 participants
Conditions and interventions
Conditions
Interventions
- BG-68501 Drug
- BGB-43395 Drug
- Fulvestrant Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 10, 2024
- Primary completion
- Mar 31, 2028
- Completion
- Jun 30, 2028
- Last update posted
- Apr 21, 2026
2024 – 2028
United States locations
- U.S. sites
- 6
- U.S. states
- 6
- U.S. cities
- 6
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Hoag Memorial Presbyterian | Newport Beach | California | 92663-4162 | Recruiting |
| Florida Cancer Specialists and Research Institute | Lake Mary | Florida | 32746-2115 | Completed |
| Washington University School of Medicine | St Louis | Missouri | 63110-1010 | Recruiting |
| Titan Health Partners Llc Dba Astera Cancer Care | East Brunswick | New Jersey | 08816-4096 | Recruiting |
| Avera Cancer Institute | Sioux Falls | South Dakota | 57105-2108 | Recruiting |
| Mary Crowley Cancer Research | Dallas | Texas | 75230 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 18 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06257264, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 21, 2026 · Synced May 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06257264 live on ClinicalTrials.gov.